Clinical manifestations, diagnosis and treatment of gout in the practice of a primary care physician

Currently, there is a significant increase in the incidence of gout, which is often combined with diabetes, hypertension, obesity, and atherosclerosis, being pathogenetically closely related to them. The increase in the incidence of gout seems to be associated with an increase in the number of patients with hyperuricemia, which is the main factor leading to the development of the disease. Knowledge of risk factors for gout, its clinical manifestations, methods of diagnosis and treatment is very important for a primary outpatient physician, since early diagnosis and adequate therapy of the disease, as well as concomitant pathology, prevents the development of severe cardiovascular complications and complications of gout itself. Currently, both international and national guidelines for the management of gout patients have been developed. The recommendations reflect the main symptoms of gout, features of the course of acute gouty arthritis depending on the patient's gender, as well as changes in the kidneys associated with hyperuricemia. The issues of diagnostics, prevention of the progression of the pathological process, and competent administration of anti-inflammatory and urat-lowering therapy are covered in detail. The article presents the risk factors for the development of gout. Much attention is paid to the description of the main clinical manifestations of gout both in the early stages of its development (acute gouty arthritis) and later (chronic tofus gout). The article presents diagnostic criteria for gout developed by ACR/EULAR, as well as methods of laboratory and instrumental diagnosis of the disease available to the primary outpatient physician. Gout therapy (non-drug and medication) is also multi-purpose. Its main directions (relief of an acute attack, prevention of relapses, urate-lowering therapy and indications for it) are reflected in the article in accordance with current national and international recommendations.

1. Denisov I.N., Chegaeva T.V., Zaugolnikova T.V. et al. Diagnosis and treatment of gout in a General practice. Clinical recommendations for General practitioners (family doctors). Moscow; 2015. (In Russ.) Available at: http://gpfm.ru/assets/image%20for%20events/podagra.PDF.

2. Barskova V.G. Chronic gout: causes of development, clinical manifestations, treatment. Terapevticheskiy arkhiv = Therapeutic archive. 2010;82(1):64-68. (In Russ.) Available at: http://www.fesmu.ru/elib/Article.aspx?id=217195.

3. Perez-Ruiz F., Martinez-Indart L., Carmona L., Herrero-Beites A.M., Pijoan J.I., Krishan E. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2013;73(1):177-182. doi: 10.1136/annrheumdis-2012-202421.

4. Bardin T., Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15:123. doi: 10.1186/s12916-017-0890-9.

5. Nielsen S.M., Bartels E.M., Henriksen M., Wahrens E., Gudbergsen H., Bliddat H. et al. Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Ann Rheum Dis. 2017;76:1870-1882. doi: 10.1136/annrheumdis-2017-211472.

6. Marson P., Pasero G. Some historical remarks on microcrystalline arthritis (gout and chondrocalcinosis). Reumatismo. 2011;63(4):199-206. doi: 10.4081/reumatismo.2011.199.

7. Roddy E., Doherty M. Gout. Epidemiology of gout. Arthritis Res Ther. 2010;12(6):223. doi: 10.1186/ar3199.

8. Eliseev M.S., Barskova V.G., Nasonova V.A. Metabolic syndrome clinical sense in gout. Klinicheskaya gerontologiya = Clinical Gerontology. 2006;(2):29-33. (In Russ.) Available at: https://elibrary.ru/item.asp?id=11642954.

9. Juraschek S.P., Miller E.R., Gelber A.C. Body mass index, obesity, and prevalent gout in the United States in 1988-1994 and 2007-2010. Arthritis Care Res. 2013;65(1):127-132. doi: 10.1002%2Facr.21791.

10. Choi H.K., Mount D.B., Reginato A.M. Pathogenesis of Gout. Ann Intern Med. 2005;143(7):499-516. doi: 10.7326/0003-4819-143-7-200510040-00009.

11. Eliseev M.S., Chikalenkova N.A., Barskova V.G. Clinical features of gout in women: the results of a comparative study. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(2):178-182. (In Russ.) doi: 10.14412/1995-4484-2014-178-182.

12. Bingham C., Ellard S, van't Hoff W.G., Simmonds A., Marinaki A.M., Badman M.K. et al. Atypical familial juvenile hyperuricemic nephropathy associated with a hepatocyte nuclear factor-1 beta gene mutation. Kidney International. 2003;63(5):1645-1651. doi: 10.1046/j.1523-1755.2003.00903.x.

13. Johnson R.J., Rideout B.A. Uric acid and diet - insights into the epidemic of cardiovascular disease. N Engl J Med. 2004;350:1071-1073. Available at: https://www.nejm.org/doi/full/10.1056/NEJMp048015.

14. Denisov I.S., Eliseev M.S., Barskova V.G. Gout Outcomes. A review of literature. Part I. Gout: Epidemiology, risk factors, course of the disease with the development of chronic tofus form. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(5):569-573. (In Russ.) doi: 10.14412/1995-4484-2013-1550.

15. Zhu Y., Pandya B.J., Choi H.K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136-3141. doi: 10.1002/art.30520.

16. Shoji A., Yamanaka H., Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321-325. doi: 10.1002/art.20405.

17. Eliseev M.S. Algorithm for diagnosis and treatment of gout. RMZH = RMJ. 2015;(7):410-416. (In Russ.) Available at: https://www.rmj.ru/articles/revmatologiya/Algoritm_diagnostiki_i_lecheniya_podagry.

18. Dalbeth N., Phipps-Green A., Frampton C., Neogi T., Taylor W.J., Merriman T.R. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Ann Rheum Dis. 2018;77:1048-1052. doi: 10.1136/annrheumdis-2017-212288.

19. Schumacher H.R., Taylor W., Edwards L., Grainger R., Schlesinger N., Dalbeth N. et al. Outcome domains for studies of acute and chronic gout. J Rheumatol. 2009;36(10):2342-2345. doi: 10.3899/jrheum.090370.

20. Neogi T. Gout. N Engl J Med. 2011;364(5):443-452. doi: 10.1056/NEJMcp1001124.

21. Roughley M.J., Belcher J., Mallen C.D., Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17(1):90. doi: 10.1186/s13075-015-0610-9.

22. Pascual E., Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis. 2007;66(8):1056-1058. doi: 10.1136/ard.2006.060368.

23. Richette P., Bardi T. Gout. Lancet. 2010;375(9711):318-328. doi: 10.1016/S0140-6736(09)60883-7.

24. Mazurov V.I. (ed.). Diseases of the joints: guidelines for physicians. Saint Petersburg: SpetsLit; 2008. 397 p. (In Russ.) Available at: https://speclit.su/image/catalog/978-5-299-00352-9/978-5-299-00352-9.pdf.

25. Neogi T., Jansen T., Dalbeth N., Fransen J., Schumacher H., Berendsen D. et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789-1798. doi: 10.1136/annrheumdis-2015-208237.

26. Qaseem A., Harris R.P., Forciea M.A. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017;166(1):58-68. doi: 10.7326/M16-0570.

27. Richette P., Doherty M., Pascual E., Barskova V., Becce F., Castaneda-Sanabria J. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707.

28. Yakupova S.P. Gout. New diagnostic and treatment options. Terapevticheskiy arkhiv = Therapeutic archive. 2018;90(5):88-92. (In Russ.) doi: 10.26442/terarkh201890588-92.

29. Eliseev M.S., Zhelyabina O.V. The influence of vegetable products on the level of uric acid: a review of literature. Terapiya = Therapy. 2017;(4):52-58. (In Russ.) Available at: https://therapy-journal.ru/ru/archive/article/35040.

30. Stamp L.K., Day R.O., Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheum. 2016;12(4):235-242. doi: 10.1038/nrrheum.2015.132.

31. Stamp L.K., O'Donnell J.L., Zhang M., James J., Frampton C., Barclay M.L., Chapman P. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63(2):412-421. doi: 10.1002/ art.30119.

32. Eliseev M.S. Updated EULAR recommendations for the management on certain items. Comments on some positions. Nauchno-prakticheskaya rev-matologiya = Rheumatology Science and Practice. 2017;55(6):600-609. (In Russ.) doi: 10.14412/1995-4484-2017-600-609.

33. Fedorova A.A., Barskova V.G., Yakunina I.A., Nasonova V.A. Short term administration of glucocorticoids in patients with protracted and chronic gout arthritis. Part III - frequency of adverse events. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2009;47(2):38-42. (In Russ.) doi: 10.14412/1995-4484-2009-457.

34. Richette P., Bardin T. Colchicine for the treatment of gout. Expert Opin Pharmacother. 2010;11(17):2933-2938. doi: 10.1517/14656566.2010.529432.

35. Becker M.A., MacDonald P.A., Hunt B.J., Lademacher C., Josef-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):585-591. doi: 10.1080/15257770802136032.

36. Terkeltaub R.A. Colchicine update: 2008. Semin Arthritis Rheum. 2009;38(6):411-419. doi: 10.1016/j.semarthrit.2008.08.006.

37. Wortmann R.L., Macdonald P.A., Hunt B., Jackson R.L. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010;32(14):2386-2397. doi: 10.1016/j.clinthera.2011.01.008.

38. Becker M.A., Schumacher H.R., Espinoza L.R. et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63. doi: 10.1186/ar2978.

39. Yu J., Qiu Q., Liang L., Yang X., Xu H. Prophylaxis of acute flares when initiating febuxostat for chronic gouty arthritis in a real-world clinical setting. Mod Rheumatol. 2018;28(2):339-344. doi: 10.1080/14397595.2017.1318467.

40. Schumacher H.R. Jr., Becker M.A., Lloyd E., MacDonald P.A., Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48(2):188-194. doi: 10.1093/rheumatology/ken457.

41. Lipsky P.E., Calabrese L.H., Kavanaugh A., Sundy J.S., Wright D., Wolfson M., Becker M.A. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16(2):R60. doi: 10.1186/ar4497.